Janssen-Cilag's HIV drug gets EU regulatory panel's nod
A European regulatory panel recommended granting approval to a treatment for HIV infection developed by Janssen-Cilag International, a unit of U.S. drugmaker Johnson & Johnson.
from Biotech News
0 Comments